US Edition
Lubrizol Announces an Important Milestone for Its Novel Patented Excipient, Apisolex™ Polymer - Pharma Excipients
Summary by Pharma Excipients
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Lubrizol Announces an Important Milestone for Its Novel Patented Excipient, Apisolex™ Polymer - Pharma Excipients
Press Release June 9, 2025 CLEVELAND, Ohio — Lubrizol announces that an Apisolex polymer excipient-enabled drug formulation is in Phase 1 clinical trials. Introduced to the market in 2022, Apisolex polymer excipient is a polyamino acid-based polymer that enhances the solubility of BCS Class II and IV active pharmaceutical ingredients (API). Apisolex polymer excipient is manufactured following Good Manufacturing Practices (GMP) guidelines and can…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
